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All organisms have devised strategies to counteract
energy depletion and promote fitness for survival.
We show here that cellular energy depletion puts
into play a surprising strategy that leads to absorption
of exogenous fuel for energy repletion. The energy-
depletion-sensing kinase AMPK binds, phosphory-
lates, and activates the transcriptional coactivator
SRC-2, which in a liver-specific manner promotes
absorption of dietary fat from the gut. Hepatocyte-
specific deletion of SRC-2 results in intestinal fat
malabsorption and attenuated entry of fat into the
blood stream. This defect can be attributed to
AMPK- and SRC-2-mediated transcriptional regula-
tion of hepatic bile acid (BA) secretion into the gut,
as it can be completely rescued by replenishing intes-
tinalBAorbygenetically restoring the levelsofhepatic
bile salt export pump (BSEP). Our results position the
hepatic AMPK-SRC-2 axis as an energy rheostat,
which upon cellular energy depletion resets whole-
body energy by promoting absorption of dietary fuel.
INTRODUCTION
In the last three decades, the rate of adult obesity in the U.S. has
doubled, and that of childhood obesity has tripled (Ogden et al.,
2006). Obesity-associated comorbidities such as diabetes, heart
disease, neurodegeneration, and certain cancers have seen
a proportional increase in incidence, along with a rise in the
percentage of the gross domestic product spent to treat them
(Ogden et al., 2006). The incessant drive of the mammalian
body to obtain and store energy is likely the result of a period
during evolution when food was scarce (Spiegelman and Flier,
2001). Clearly, one of the more important challenges of the
current decade is to enhance our understanding of the basic
mechanisms of energy homeostasis in order to gain a deeper
insight into the factors that influence body weight. DecodingCthese factors in mechanistic and molecular terms has great
potential for unearthing preventative and therapeutic targets
against obesity.
One of the key survival strategies employed by organisms
appears to be responding to cellular energy depletion by acti-
vating pathways that correct the depletion (Carling, 2004; Hardie
and Carling, 1997; Kahn et al., 2005). Two ways to correct
cellular energy depletion are deactivation of processes that
consume ATP and activation of processes that produce ATP.
An ancient energy sensor, AMP-activated protein kinase
(AMPK), appears to do just that, by deactivation of ATP-
consuming anabolic processes and activation of ATP-producing
catabolic processes (Carling, 2004; Hardie and Carling, 1997;
Kahn et al., 2005; Viollet et al., 2006). Since exogenous fuel is
essential for ATP synthesis, it is no surprise that AMPK also
drives appetite (Carling, 2004). We show here that once the
exogenous fuel is eaten, AMPK, via a previously unlinked
systemic process, allows for optimal absorption of the most
energy-rich fuel: dietary fat. AMPK activates the transcriptional
coactivator SRC-2, which, as we demonstrate, promotes
absorption of dietary fat by transcriptional modulation of hepatic
bile acid (BA) secretion. The mechanistic cascade we describe
links the cellular energy status with the whole-body energy state.
Since SRC-2 has been described to modulate energy loss via
deactivation of brown adipose tissue (Picard et al., 2002), our
current results position it as a regulator of energy uptake and,
thus, as a holistic controller of energy homeostasis.RESULTS
Whole-Body Ablation of SRC-2 Results in Dietary Fat
Malabsorption
Global SRC-2 (TIF2) null mice are protected from high-fat-diet-
mediated obesity because the coactivator promotes energy
conservation by inhibiting brown adipose tissue activation
(Picard et al., 2002). We hypothesized that SRC-2 might play
an additional role in energy intake and assessed food intake
and fat absorption. Male SRC-2/ mice fed standard chow
ad libitum for 24 hr following an overnight fast were compared
with WT littermates for food intake, fecal mass, fecal triglycerideell Metabolism 13, 35–43, January 5, 2011 ª2011 Elsevier Inc. 35
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Figure 1. Whole-Body Ablation of SRC-2
Results in Dietary Fat Malabsorption
(A–D) Food intake, fecal output, fecal triglycerides,
and plasma triglycerides were measured in WT
and SRC-2/ mice (whole-body ablation) fed
standard chow ad libitum for 24 hr following an
overnight fast (n = 5 mice per group). Data are rep-
resented as mean + SEM. Unpaired Student’s
t test was used for evaluation of statistical signifi-
cance. One asterisk indicates p < 0.05, two aster-
isks p < 0.01, and three asterisks p < 0.001.
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Cellular Energetics Influence Whole-Body Energycontent, and plasma triglyceride content. Whole-body ablation
of SRC-2 did not affect food intake, but increased fecal mass
and triglyceride content with a concomitant decrease in plasma
triglycerides (Figures 1A–1D), suggesting a reduced capacity to
absorb dietary fat from the gut.Hepatocyte-Specific Ablation of SRC-2 Results
in Intestinal Fat Malabsorption, which Can Be Rescued
by Replenishing Gut BA Levels
Hepatocyte-specific SRC-2 knockout mice (SRC-2 LKO) (Fig-
ure S1A) consumed the same amount of standard chow per
day as their WT counterparts, but also showed increased fecal
mass and triglyceride content with a plasma triglyceride deficit
(Figures 2A–2D), suggesting the liver to be the site of SRC-2
action for intestinal fat absorption. Fecal lipase activity was
unaltered in SRC-2 LKO, indicating that pancreatic exocrine
function was unaffected by hepatic ablation of SRC-2 (Fig-
ure S1B). Based on the reciprocal effects on fecal and plasma
triglycerides in the SRC-2 LKO mice, we assessed the rate of
triglyceride entry into the plasma after oral gavage with olive oil
labeled with C14 (after injection with Tyloxapol to inhibit plasma
lipolysis). Indeed, we found lower triglyceride and radioactivity
levels in the plasma of SRC-2 LKO mice (Figures 2E and 2F).
We also examined intestinal radioactivity after gavaging SRC-2
LKO and WT mice with olive oil labeled with 14C and found
a 2-fold deficit in proximal jejunal radioactivity (Figure 2G), sug-
gesting reduced absorption of triglycerides from the gut lumen
into the enterocytes. Consistent with this, frozen sections of
the proximal jejunal villi stained with oil red O showed a signifi-
cantly lower level of triglyceride staining in SRC-2 LKO mice
upon exposure to an olive oil gavage (Figure S1C). We conclude
that intestinal fat absorption is defective in SRC-2 LKO mice.
Since decreased hepatic BA secretion into the gut could
account for this intestinal effect of hepatic SRC-2 deletion, we
fed mice either standard chow or a 1% cholic acid (CA) diet for
14 days to inhibit hepatic BA production and assessed BA levels
in plasma, liver, and bile. Both standard-chow-fed and CA-diet-
fed SRC-2 LKO mice displayed increased hepatic BA but
decreased biliary BA levels (Figures 2H and 2I), consistent with
decreased hepatic BA secretion into the gut. Plasma BA levels
were elevated in the CA-fed SRC-2 LKO mice (Figure S1D).
Consistent with an elevation in hepatic BA content and a deficit
in biliary BA levels, the total BA pool size remained unchanged,36 Cell Metabolism 13, 35–43, January 5, 2011 ª2011 Elsevier Inc.along with an unchanged biliary BA composition profile (Figures
S1E and S2A). Plasma bilirubin levels remained unchanged as
well (Figure S1G). To test whether the failure of BA to reach the
gut in sufficient amounts caused the observed fat malabsorp-
tion, we assessed fecal triglycerides from SRC-2 LKO mice
and WT littermates fed either a high-fat diet to stress the fat
absorption apparatus or a high-fat diet plus 1% CA to correct
the gut BA deficiency. Fecal samples from SRC-2 LKO mice
contained 2-fold more triglycerides than samples fromWT litter-
mates on high-fat challenge (Figure 2J). Remarkably, this fat
malabsorption was completely rescued in SRC-2 LKO mice
that were fed exogenous BA (Figure 2J). In order to rule out the
possibility that potentially enhanced peripheral energy
consumption might account for the low plasma triglyceride
levels in SRC-2 LKO mice, we measured oxygen consumption
(VO2). The VO2 levels over a 24 hr period remained unchanged
between WT and SRC-2 LKO mice (Figure S1F).SRC-2 Regulates the Expression of BSEP, Forced
Hepatic Restoration of which Can Rescue the Fat
Malabsorption Secondary to SRC-2 Ablation
Accumulation of liver and plasma BA and their deficit in bile led
us to conclude that SRC-2 positively regulates BA secretion
from the liver into the gut. Accordingly, we investigated expres-
sion of a series of hepatic transporters, including the bile salt
export pump (BSEP), themajor BA transporter from hepatocytes
to the bile ducts, in chow-fed mice and mice challenged with the
CA diet. Consistent with previously published liver microarray
results with whole-body SRC-2 null mice (Jeong et al., 2006),
BSEP mRNA and protein levels were significantly decreased in
SRC-2 LKO mice (Figures 3A and 3B). The basolateral trans-
porter OSTb was also decreased. The BSEP effect is specific
for SRC-2, since its expression was not affected by SRC-1 or
SRC-3 deletion (Figure S3A), demonstrating the specificity of
coactivator function in vivo. Particularly as BSEP deficiency in
humans is accompanied by severe steatorrhea (Walkowiak
et al., 2006), the deficit in BSEP expression likely explains fat
malabsorption in SRC-2 LKO mice.
We assessed the expression of a number of other key genes
involved in BA homeostasis and found a deficit in the expression
of BA biosynthesis and import genes (Cyp7a1, Cyp8b1, Cyp7b1,
Cyp27a1, NTCP) in SRC-2 LKO mice that suggested a compen-
satory reduction in gene expression in response to excess
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Figure 2. Hepatic SRC-2 Modulates Dietary
Fat Absorption in a BA-Dependent Manner
(A–D) Food intake, fecal output, fecal triglycerides,
and plasma triglycerides were measured in WT
and SRC-2 LKO mice (liver-specific ablation) fed
standard chow ad libitum for 24 hr following an
overnight fast (n = 5 mice per group).
(E and F) Plasma radioactivity and triglyceride
levels were measured in chow-fed WT and SRC-
2 LKO mice after injection of the lipase inhibitor
Tyloxapol and gavage with olive oil containing
14C-trioleoylglycerol (n = 5 mice per group). Data
are represented as mean + SEM. Two-way
ANOVA with Bonferroni posttests to compare
replicate means by row was used for evaluation
of statistical significance. One asterisk indicates
p < 0.05, two asterisks p < 0.01, and three aster-
isks p < 0.001.
(G) Intestinal radioactivity levels were measured in
WT and SRC-2 LKO mice 2 hr after gavage with
olive oil containing 14C-trioleoylglycerol (n = 5
mice per group). Data are represented as
mean + SEM. Two-way ANOVA with Bonferroni
posttests to compare replicate means by row
was used for evaluation of statistical significance.
One asterisk indicates p < 0.05, two asterisks
p < 0.01, and three asterisks p < 0.001.
(H and I) Hepatic and biliary BA levels were
measured in WT and SRC-2 LKO mice on stan-
dard chow and on 1% CA diet for 2 weeks. Bile
was obtained from the gall bladder and is repre-
sentative of intestinal BA levels (n = 4–5 mice per
group).
(J) Fecal triglyceride levels were measured in
chow-fed WT and SRC-2 LKO mice upon expo-
sure of mice to a high-fat diet (60% calories from
fat) and a diet containing high fat plus 1% CA for
48 hr (n = 4–5 mice per group). Data are repre-
sented as mean + SEM. Unless otherwise indi-
cated, unpaired Student’s t test was used for eval-
uation of statistical significance. One asterisk
indicates p < 0.05, two asterisks p < 0.01, and
three asterisks p < 0.001. See also Figures S1
and S2.
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Cellular Energetics Influence Whole-Body Energyhepatic BA levels (Figure S3B). A decrease in the BA catabolic
pathway should increase cholesterol levels, and plasma total
cholesterol, HDL, LDL, and hepatic total cholesterol showed
significant accumulation in SRC-2 LKO mice (Figure S3D). This
was unaccompanied by a change in intestinal absorption of
dietary cholesterol (Figure S3C). While HDL accumulation could
suggest involvement of extra-hepatic tissues, this is unlikely, as
SRC-2 is deleted specifically in the liver. Exploring cholesterol
metabolism in more detail, we assessed the expression of
several genes important for maintaining cholesterol homeostasis
in the liver and the intestine (Figure S3E). We found a deficit in
liver ABCG5 and ABCG8 in SRC-2 LKOmice, potentially explain-
ing plasma and hepatic cholesterol accumulation, as ABCG5
and ABCG8 are necessary for cholesterol excretion into the
bile (Figure S3E). Expression of LDLR and SR-B1, genes
involved in liver cholesterol import, was suppressed in SRC-2CLKOmice (Figure S3F), possibly to compensate for the increased
hepatic cholesterol content, and likely explains accumulation of
plasma cholesterol. Assessment of the expression of transcrip-
tion factors relevant to BA and cholesterol homeostasis showed
no significant differences between SRC-2 LKO and WT mice
(Figure S3G). Consistent with an unchanged plasma VLDL
profile, the expression of several genes important for hepatic
VLDL assembly and export showed no change in SRC-2 LKO
mice compared with WT (Figure S4A).
We tested whether reduced hepatic BSEP expression was
responsible for the BA perturbation and fat malabsorption in
SRC-2 LKO mice by restoring hepatic BSEP to physiological
levels using an adenoviral vector. Notably, BSEP restoration
completely reversed the hepatic BA accumulation, as well as
the fecal triglyceride accumulation and plasma triglyceride
deficits displayed by SRC-2 LKO mice (Figures 3C–3F).ell Metabolism 13, 35–43, January 5, 2011 ª2011 Elsevier Inc. 37
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Figure 3. SRC-2 Modulates Dietary Fat
Absorption by Controlling the Expression
of the BSEP
(A) Expressionof variousBA transporter geneswas
measured via relative quantitation by quantitative
PCR in the liver of WT and SRC-2 LKO mice that
were exposed to standard chow or 1% CA for
2 weeks (n = 5–7 mice per group). Data are repre-
sented as mean + SEM. Unpaired Student’s t test
was used for evaluation of statistical significance.
One asterisk indicates p < 0.05, two asterisks
p < 0.01, and three asterisks p < 0.001.
(B) BSEP protein expression was measured via
western blot analysis in the liver of WT and SRC-
2 LKO mice that were exposed to standard chow
(n = 2 mice per group). GAPDH was used as
a loading control.
(C–F) SRC-2 LKO mice exposed to adenoviral
BSEP (Ad. BSEP) were compared with SRC-2
LKO and WT mice exposed to empty adenovirus
(Ad. Empty) using tail vein infusion. Eight days after
virus infusion, hepatic BSEP expression, hepatic
BA content, fecal triglyceride content, and plasma
triglyceride content weremeasured (n = 6mice per
group). Statistical comparison was performed
between WT (Ad. Empty) and SRC-2 LKO
(Ad. Empty) and between SRC-2 LKO (Ad. Empty)
and SRC-2 LKO (Ad. BSEP) groups. Data are rep-
resented as mean + SEM. One-way ANOVA with
Tukey’s multiple comparison test was used for
evaluation of statistical significance. One asterisk
indicates p<0.05, twoasterisks p<0.01, and three
asterisks p < 0.001. See also Figures S3 and S4.
Cell Metabolism
Cellular Energetics Influence Whole-Body EnergySRC-2 Modulates BSEP Expression
in a Cell-Autonomous Manner by Coactivating FXR
To rule out an indirect, systemic effect of hepatic SRC-2 ablation
on the bile secretion program, we investigated primary hepato-
cytes (PHs) isolated from SRC-2 LKO and WT mice exposed to
either vehicle or chenodeoxycholic acid (CDCA) (Lew et al.,
2004). We found reductions in mRNA levels of BSEP and OSTb
in SRC-2 null PHs that mirrored those found in vivo (Figure 4A),
demonstrating a cell-autonomous effect of SRC-2 on the
expression of these genes. Repeating this experiment in PHs
following acute SRC-2 knockdown demonstrated very similar
results, reaffirming the critical nature of SRC-2 for the expression
of the hepatic bile secretion program (Figure S5A).
The BSEP promoter has an evolutionarily conserved recogni-
tion motif for the nuclear receptor FXR (Ananthanarayanan et al.,
2001), and we found that SRC-2 synergized with FXR for BSEP
promoter activation (Figure 4B). We examined the role of the38 Cell Metabolism 13, 35–43, January 5, 2011 ª2011 Elsevier Inc.two activation domains (ADs) of SRC-2
in BSEP transactivation by using deletion
mutants for AD1, AD2, and both. Interest-
ingly, we found that AD1 is absolutely
essential for SRC-2-mediated transacti-
vation of the BSEP promoter (Figure 4C).
Using in vivo chromatin immunoprecipi-
tation (ChIP) (Figures 4D and 4E), we
confirmed that SRC-2 is recruited to the
BSEP promoter in the liver, and this was
abolished in the absence of FXR.To unequivocally demonstrate the specificity of SRC-2, we per-
formed in vivo ChIP assays probing SRC-1 and SRC-3 occu-
pancy of the BSEP promoter. In contrast with SRC-2, we found
an absence of SRC-1 and SRC-3 at the BSEP prompter (Fig-
ure S5B). Consistent with this, we found unchanged plasma
BA levels in SRC-1 and SRC-3 null mice and unchanged plasma
triglyceride levels in SRC-3 null mice (Figure S5C). We found
a significant reduction in plasma triglyceride levels in SRC-1
null mice (Figure S5C). However, with no change in plasma BA
content as well as BSEP expression, it is unlikely that the reduc-
tion in plasma triglycerides in SRC-1 null mice is due to altered
BA homeostasis, as is the case in SRC-2 LKO mice.
A Hepatocyte-Specific Screen Identifies AMPK
as a Positive Modulator of BSEP Expression
Having substantiated the signaling downstream of SRC-2
that leads to BA secretion and dietary fat absorption, we
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Figure 4. SRC-2 Modulates BSEP Expression in a Cell-Autonomous
Manner by Coactivating FXR
(A) Expression of various BA transporter genes was measured via relative
quantitation by quantitative PCR in primary hepatocytes exposed to DMSO
or to CDCA from WT and SRC-2 LKO mice. Statistical comparison was per-
formed between WT and SRC-2 KO PHs in each treatment group.
(B) HepG2 liver hepatoma cells were transfected with a reporter-gene plasmid
driven by the wild-type mouse BSEP promoter and the same promoter with
a mutated FXRE motif, together with expression plasmids for SRC-2 and
FXR, and exposed to CDCA. Reporter-gene levels were determined 48 hr after
transfection. The empty vector (EV) value was fixed at 1, and the rest of the
values are compared relative to that.
(C) HepG2 liver hepatoma cells were transfected with a reporter-gene plasmid
driven by the wild-type mouse BSEP promoter together with expression plas-
mids for WT SRC-2, SRC-2 mutant with AD1 deletion, SRC-2 mutant with AD2
deletion, and SRC-2 mutant with both AD1 and AD2 deletions and FXR and
exposed to CDCA. Reporter-gene levels were determined 48 hr after trans-
fection. The empty vector (EV) value was fixed at 1, and the rest of the values
are compared relative to that.
(D) In vivo ChIP assays were performed using liver tissue from WT mice with
150–200 bp amplicons flanking the region containing the FXRE motif of the
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Chypothesized that because SRC-2 promotes energy intake
(via dietary fat absorption) and counteracts energy loss (via
deactivation of brown adipose tissue) (Picard et al., 2002), it
could itself be responsive to changes in energy status. We per-
formed a screen to assess whether a number of hormones and
cellular factors known to play a role in energy homeostasis could
affect BSEP expression in PHs. We found that AICAR, the acti-
vator of the well-known sensor of cellular energy depletion,
AMPK (Carling, 2004; Hardie and Carling, 1997; Kahn et al.,
2005; Viollet et al., 2006), strongly affected BSEP expression
(Figure 5A). Because of the possibility that AICAR may have
promiscuous effects that are independent of AMPK, we overex-
pressed a constitutively active form of AMPK in PHs (with no
AICAR present) and found it to be sufficient to transactivate
BSEP (Figure 5B). Conversely, overexpressing a dominant-
negative form of AMPK (DnAMPK) resulted in downregulation
of BSEP expression (Figure 5B). DnAMPK overexpression also
resulted in attenuation of AICAR-mediated BSEP transactivation
(Figure 5C).
AMPK Binds, Phosphorylates, and Increases SRC-2’s
Intrinsic Transcriptional Activity and Drives It to the
BSEP Promoter
AMPK activation in HepG2 cells using AICAR increased the
intrinsic transcriptional activity of SRC-2, while cAMP potentia-
tion by forskolin addition had no effect (Figures 6A and S6A).
Interfering with AMPK activity using a dominant-negative
construct abrogated AICAR-mediated SRC-2 activation (Fig-
ure 6B), confirming the specificity of AICAR. AICAR had no effect
on SRC-2 protein levels (Figure S6B), suggesting an activation
mechanism independent of enhanced SRC-2 expression. Using
coimmunoprecipitation (coIP) assays, we found a physical asso-
ciation between endogenous SRC-2 and AMPK proteins (Fig-
ure 6C). This association was unaffected by AICAR (Figure 6C),
suggesting an activation mechanism independent of increased
affinity. Using in vitro kinase assays with purified, full-length
SRC-2 and AMPK proteins, we found that AMPK phosphory-
lated SRC-2 in an AMP-dependent manner (Figure 6D).
We next investigated the impact of loss of AMPK in vivo upon
BSEP expression. We found a deficit in BSEPmRNA and protein
levels in liver tissue from AMPKa1/2 double knockout mice,
along with a modest accumulation of hepatic BA (Figures 6E,
6F, and S6C,). Consistent with this, AICAR treatment of mice
increased hepatic BSEP mRNA and protein expression (Figures
6G and S6D), suggesting that AMPK regulates BSEP expression
in vivo, presumably through an SRC-2-mediated effect. Indeed,BSEP promoter and an irrelevant region 3000 bp upstream of the transcription
start site. SYBR Green quantitative PCR (normalized to input) was used to
assess SRC-2 occupancy of the BSEP promoter, using two different anti-
bodies that targeted different regions of SRC-2. Control antibody recognized
mouse IgG.
(E) In vivo ChIP assays were performed using liver tissue from WT and FXR
knockout mice with primers flanking the region containing the FXRE motif of
the BSEP promoter. SYBR Green quantitative PCR (normalized to input) was
used to assess SRC-2 occupancy of the BSEP promoter, using an SRC-2-
specific antibody. Control antibody recognized mouse IgG. Data are
represented as mean + SEM. For all gene expression data, unpaired Student’s
t test was used for evaluation of statistical significance. One asterisk indicates
p < 0.05, two asterisks p < 0.01, and three asterisks p < 0.001. See also
Figure S5.
ell Metabolism 13, 35–43, January 5, 2011 ª2011 Elsevier Inc. 39
V
e
h
ic
le
G
a
s
tr
in
N
P
Y
G
IP
G
L
P
1
G
L
P
2
N
e
u
r
o
m
e
d
in
P
Y
Y
S
e
c
r
e
ti
n
O
r
e
x
in
G
h
r
e
li
n
L
e
p
ti
n
C
C
K
S
o
m
a
to
s
ta
ti
n
A
IC
A
R
N
A
D
0
10
20
30
40
*
R
e
l
a
t
i
v
e
B
S
E
P
m
R
N
A
A
B
G
F
P
C
a
t.
A
c
ti
v
e
A
M
P
K
a
D
o
m
.
N
e
g
a
ti
v
e
A
M
P
K
a
0
10
20
30
40
*** ***
R
e
l
a
t
i
v
e
A
M
P
K
a
m
R
N
A
G
F
P
C
a
t.
A
c
ti
v
e
A
M
P
K
a
D
o
m
.
N
e
g
a
ti
v
e
A
M
P
K
a
0.0
2.5
5.0
7.5 *
*
R
e
l
a
t
i
v
e
B
S
E
P
m
R
N
A
V
e
h
ic
le
A
IC
A
R
0
2
4
6
8
10
12
GFP
DnAMPK
*
**
R
e
l
a
t
i
v
e
B
S
E
P
m
R
N
A
C
Figure 5. A Hepatocyte-Specific Screen Identifies AMPK as a Puta-
tive, Positive Modulator of BSEP Expression
(A) BSEP expression was measured via relative quantitation by quantitative
PCR in primary hepatocytes exposed to standard doses of the indicated
agents for 24 hr.
(B) BSEP expression was measured via relative quantitation by quantitative
PCR in primary hepatocytes exposed to adenoviruses containing cDNAs
representing either constitutively active AMPKa or dominant-negative AMPKa
for 24 hr. Statistical comparison was made between the GFP group and either
the constitutively active AMPKa or dominant-negative AMPKa groups.
(C) BSEP expression was measured via relative quantitation by quantitative
PCR in primary hepatocytes exposed to an adenovirus containing cDNA rep-
resenting dominant-negative AMPKa and either vehicle or 1 mM AICAR for
18 hr. All gene expression data are represented as mean + SEM. Unpaired
Student’s t test was used for evaluation of statistical significance. One asterisk
indicates p < 0.05, two asterisks p < 0.01, and three asterisks p < 0.001.
Cell Metabolism
Cellular Energetics Influence Whole-Body Energywe found SRC-2 to be necessary for AICAR-mediated BSEP and
OSTb transactivation in PHs (Figures 6H and S6E). We also
found FXR to be necessary for AICAR-mediated BSEP transac-
tivation (Figure S6F), suggesting that the SRC-2-FXR complex
plays a key role in transducing signals from AMPK to the BSEP
promoter. AICAR was also able to activate SRC-1 and SRC-3
in vitro (Figure S6G), but since SRC-1 and SRC-3 do not impact
BSEP transactivation in vivo (Figures S3A, S5B, and S5C), this
might suggest distinct AMPK-mediated functions exerted via
the other p160 family members. In cultured liver cells, AICAR
treatment resulted in increased SRC-2 recruitment to the
BSEP promoter (Figure 6I). Surprisingly, it also drove AMPKa2 it-40 Cell Metabolism 13, 35–43, January 5, 2011 ª2011 Elsevier Inc.self to the BSEP promoter (Figure 6J), suggesting that AMPK, in
addition to increasing the intrinsic transcriptional activity of
SRC-2, recruits SRC-2 to the BSEP promoter and also accom-
panies it there. This is consistent with the predominantly nuclear
expression profile of AMPKa2 (Salt et al., 1998) and with a recent
report that demonstrates that AMPKa2 plays a direct role in tran-
scription by associating with chromatin, phosphorylating
histones, and being recruited to promoters of target genes
(Bungard et al., 2010). It is quite possible that other AMPK
subunits are also present at the BSEP promoter in association
with AMPKa2, allowing AMPK to function as a holoenzyme in
the transactivation of BSEP.
DISCUSSION
Our results have implicated the SRC-2 coactivator as an essen-
tial cog in the AMPK-mediated energy regeneration wheel. We
have elucidated a pathway that links cellular energy depletion
with the act of priming the entry of dietary fuel into the body
(Figure 7), thereby linking the cellular energy state with the
whole-animal energy state. We have shown that the cellular-
energy-depletion-sensing kinase AMPK activates the transcrip-
tional coactivator SRC-2, which in turn transactivates the BSEP
gene by synergizing with the nuclear receptor FXR, resulting in
hepatic BA secretion and downstream dietary fat absorption.
Interfering with this process by genetic deletion of SRC-2, in
a whole-body as well as a liver-specific manner, results in abro-
gation of hepatic BA secretion and fat malabsorption in the gut.
These effects can be fully rescued by correcting the gut BA defi-
ciency as well as by correcting the hepatic BSEP deficiency
genetically.
Our results suggest that AMPK promotes absorption of dietary
fat in order to provide fuel for its core cellular function of fatty-
acid oxidation and ATP regeneration (Minokoshi et al., 2002).
The cycle appears to beginwith a low cellular ATP state, presum-
ably due to a moderate drop in energy stores between meals,
which activates AMPK and SRC-2, thereby allowing the liver to
secrete BA into the gall bladder, optimally priming the gut for
triglyceride absorption from the next meal, which in turn serves
as a fuel for cellular fatty acid oxidation, thus causing ATP
synthesis and deactivation of the above cascade. There is
some precedent for ATP levels displaying circadian oscillation
(Womac et al., 2009), presumably set by periodic food intake,
while AMPK is well known to be under circadian control (Lamia
et al., 2009). By that token, we hypothesize that the cascade
we have described is activated and deactivated in a circadian
manner and is set by the circadian oscillation in ATP levels and
AMPK activation. SRC-2 demonstrates exquisite specificity in
the modulation of this pathway compared with its family
members SRC-1 and SRC-3, much like we have shown in the
past for glucose homeostasis (Chopra et al., 2008).
Since SRC-2 has been shown to oppose energy loss (Picard
et al., 2002) and our current results have implicated it in energy
uptake, it appears to function much like AMPK (Carling, 2004;
Hardie and Carling, 1997; Kahn et al., 2005) in preventing energy
depletion. Due to its holistic nature in control of energy homeo-
stasis, the AMPK-SRC-2 axis may serve as a potential target
to fine-tune whole-body energy levels and combat obesity and
associated comorbidities.
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Figure 6. Hepatic AMPK Increases the
Intrinsic Transcriptional Activity of SRC-2
and Drives It to the BSEP Promoter
(A) HepG2 liver hepatoma cells were transfected
with pG5Luc (five Gal4 binding sites driving lucif-
erase expression) together with pBIND SRC-2
(SRC-2:Gal4 DNA binding domain fusion protein)
and exposed to 1 mM AICAR. Luciferase levels
were determined 48 hr after transfection. The
vehicle value was fixed at 1, and the rest of the
values are compared relative to that.
(B) HepG2 liver hepatoma cells were transfected
with pG5Luc together with pBIND SRC-2 and
either empty vector (EV) or dominant-negative
AMPKa2 (DnAMPK) and exposed to 0.3 mM,
0.6 mM, and 1 mM AICAR. Luciferase levels
were determined 48 hr after transfection. The
vehicle value was fixed at 1, and the rest of the
values are compared relative to that.
(C) HepG2 cell were treated with 1 mM AICAR for
30 min and subjected to immunoprecipitation with
an AMPKa2-specific antibody. Immunoprecipi-
tated samples were subjected to immunoblotting
along with 10% input, as indicated.
(D) Purified, full-length SRC-2 protein was sub-
jected to in vitro phosphorylation with or without
purified AMPK holoenzyme and AMP, as indi-
cated.
(E and F) Hepatic BSEP expression and BA
content were measured via relative quantitation
by quantitative PCR in the liver of WT and
AMPKa1/a2 double knockout (AMPKa DKO)
mice that were fasted for 24 hr (n = 7–8 mice per
group).
(G) Hepatic BSEP expression was measured via
relative quantitation by quantitative PCR in the
livers of mice that were exposed to either PBS or
0.5 mg/g BW AICAR for 12 hr and fed standard
chow (n = 6 mice per group).
(H) BSEP expression was measured via relative
quantitation by quantitative PCR in primary hepa-
tocytes from WT and SRC-2 LKO mice exposed
to 1 mM AICAR for 18 hr.
(I and J) ChIP assayswere performed usingHepG2
cells exposed to either vehicle or 1 mM AICAR for
30 min with primers flanking the region containing
the FXREmotif of theBSEPpromoter. SYBRGreen
quantitative PCR (normalized to input) was used to
assess SRC-2 or AMPKa2 occupancy of the BSEP
promoter uponChIP, using anSRC-2- orAMPKa2-specific antibody.Control antibody recognizedmouse IgG.All gene expressiondata are representedasmean+
SEM. Unpaired Student’s t test was used for evaluation of statistical significance. One asterisk indicates p < 0.05, two asterisks p < .01, and three asterisks
p < 0.001. See also Figure S6.
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Mice
Whole-body SRC-1, SRC-2, and SRC-3 null mice have been described (Cho-
pra et al., 2008). We used 8- to 16-week-oldmale littermate mice for all assays.
SRC-2 F/F mice (Mukherjee et al., 2006) were crossed with Albumin-Cre mice
(Weisend et al., 2009) to generate liver-specific SRC-2 LKO mice. We used
8- to 16-week-old male SRC-2 LKO mice and sex-matched SRC-2 F/F (WT)
littermates for all in vivo studies. The results from SRC-2/mice (food intake,
fecal mass, fecal triglycerides, and plasma triglycerides) mirrored those
obtained using SRC-2 LKO mice, thereby ruling out any influence by Cre re-
combinase-mediated toxicity in SRC-2 LKO mice. For BSEP-mediated
genetic rescue experiments, WT and SRC-2 LKO mice were exposed to
adenoviral transgenesis (1011 virus particles per mouse) via tail vein injections,Cas previously described (Chopra et al., 2008). Fecal samples were collected
from individual mice using metabolic cages over a 24 hr time period 7 days
after virus infusion. Mice were sacrificed and plasma and various organs
were isolated 8 days after viral infusion. WT C57 mice were injected subcuta-
neously with AICAR (0.5 mg/g BW), and livers were isolated 12 hr later. Livers
lacking AMPK were obtained from liver-specific knockout mice described
previously (Guigas et al., 2006). Unless otherwise stated, all experiments
were performed in the 24 hr ad libitum fed state, which followed an overnight
fast to synchronize the metabolism of all mice. The Baylor College of Medicine
Institutional Animal Care and Utilization Committee approved all experiments.
Metabolic Studies
We measured plasma and biliary BA, plasma and biliary phospholipids, and
plasma triglycerides using colorimetric assays from Diagnostic Chemicalsell Metabolism 13, 35–43, January 5, 2011 ª2011 Elsevier Inc. 41
Figure 7. Schematic Depicting the Cascade that Links Cellular
Energy Depletion with Whole-Body Energy Repletion
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Cellular Energetics Influence Whole-Body EnergyLtd. (Charlottetown, PE, Canada), Wako Pure Chemicals (Richmond, VA), and
Thermo Scientific (Rockford, IL), respectively, using the manufacturer’s
protocol (bile was obtained from the gall bladders using a 26G needle and
syringe). Biliary cholesterol was measured using a colorimetric assay (MBL
International; Des Plaines, IL) following the manufacturer’s protocol. Plasma
cholesterol, HDL, LDL, VLDL, and bilirubin were measured by the Baylor
College of Medicine veterinary pathology core laboratory. Hepatic BAs were
extracted by digesting the liver in 70%ethanol followed by a colorimetric assay
(Diagnostic Chemicals Ltd.) after normalizing to liver weight. BA pool size was
determined as previously described (Tiemann et al., 2004). BA composition
was determined by HPLC using a reverse-phase C18 column with isocratic
elution at 0.75 ml/min and a methanol phosphate buffer. Conjugated BAs
were detected by absorbance at 205 nm, and identity assignments were
made by relative retention times with known standards. To ensure that nothing
escaped the HPLC system, one sample from each group of mice was run on
a nanoESI-MS system. Intestinal cholesterol absorption was determined as
previously described (Temel et al., 2005). Food intake was assessed from indi-
vidual mice using metabolic cages over a 24 hr time period. Fecal samples
were collected from individual mice using metabolic cages over a 24 hr time
period. Fecal samples were weighed and subjected to lipid extraction proce-
dures (Kolonin et al., 2004), after which triglyceride measurement was carried
out using a colorimetric assay (Thermo Scientific) after normalizing to fecal
weight. Fecal lipase activity was measured using a colorimetric kit (Bio Assay
Systems; Hayward, CA) after normalization to fecal weight. VO2 levels were
measured using individually housed mice in metabolic cages. Diets containing
1% CA, high fat (60% calories from fat), and high fat plus 1% CA were
purchased from Harlan-Teklad (Houston, TX). Assessment of intestinal triglyc-
eride uptake into the circulation and intestine using 14C-labeled olive oil has
been described (Yen et al., 2009).
Histological Analyses
We fixed liver samples in 10% formaldehyde for H&E staining. We used frozen
proximal jejunal cross-sections for oil red O staining to evaluate neutral lipid
content in intestinal villi.42 Cell Metabolism 13, 35–43, January 5, 2011 ª2011 Elsevier Inc.RNA and Protein Analysis
Weused standard RNA extraction procedures (RNeasyMini Kit fromQIAGEN).
Reverse transcription was carried out using the SuperScript III kit (Invitrogen)
using the manufacturer’s protocol. For gene expression analysis, quantitative
PCR was performed using sequence-specific primers and probes from Roche
(Universal Probe Library). GAPDH was used as an internal control for all gene
expression assays. All quantitative PCR primers are available upon request.
Protein, extracted from frozen livers using tissue lysis buffer (Pierce;
Rockford, IL), was subjected to western blot analysis using antibodies against
BSEP (Abgent; San Diego, CA) and GAPDH (Abcam; Cambridge, MA). HepG2
cell western blot and coIP analyses were performed using antibodies against
SRC-2 (Bethyl; Montgomery, TX), phospho-AMPKa2 and AMPKa2 (Cell
Signaling; Danvers, MA), and b-actin (Sigma) using standard methodology.
In Vitro Kinase Assays
We used full-length, purified SRC-2 protein along with purified AMPK holoen-
zyme (Cell Signaling) for in vitro kinase assays using the manufacturer’s
protocol (Cell Signaling).
Chromatin Immunoprecipitation
In vivo ChIP was performed by using liver tissue from WT and FXR knockout
mice previously infused with collagenase. After percol treatment to exclude
dead cells, 1% formaldehyde was added to produce crosslinking. The rest
of the ChIP procedure was performed using the EZ ChIP kit (Upstate; Billerica,
MA) following the manufacturer’s protocol. Standard ChIP procedure was fol-
lowed for experiments using HepG2 liver hepatoma cells in culture. SRC-2
antibodies are from Bethyl. AMPKa2 antibody is from Cell Signaling. Quantita-
tive PCR for ChIP was performed using the SYBR Green Technology (Applied
Biosystems; Foster City, CA) using sequence-specific primers. Results were
normalized to input in each case. Primer sequences are available on request.
Cell Culture
Primary mouse hepatocytes were isolated from 8- to 12-week-old WT and
SRC-2 LKO mice, as described previously (Chopra et al., 2008). Cells were
incubated overnight in Williams E media (Invitrogen) containing 10% FBS
before transfection with siRNA or treatment with CDCA. SMARTpool siRNA
against SRC-2 nontargeting control was purchased from Dharmacon; Lafay-
ette, CO. RNA isolation was carried out 48 hr after treatment. HepG2 cells
were transfected with a reporter-gene plasmid driven by the wild-type mouse
BSEP promoter (Zhang et al., 2003) and the same promoter with a mutation in
the FXRE (Stratagene QuikChange kit), together with expression plasmids for
WTSRC-2, FXR andwith the indicated forms of SRC-2 (WT, Activation Domain
1 deletion mutant [AD1], Activation Domain 2 deletion mutant [AD2], AD1 and
AD2 double deletion mutant [AD1/2]). Reporter-gene levels were determined
48 hr after transfection and treatment with CDCA. Constitutively active and
dominant-negative AMPK adenoviruses have been described (Woods et al.,
2000). For SRC-2 activation experiments, HepG2 cells were transfected with
pG5Luc, bBIND-SRC-2, and pBIND-empty and dominant-negative AMPK
(DnAMPK). Reporter-gene levels were determined 48 hr after transfection
and treatment with 1 mM AICAR.
Statistical Analysis
All results are presented asmean + SEM. P valueswere calculated by unpaired
Student’s t test and either one-way or two-way ANOVA where appropriate.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and can be found with this
article online at doi:10.1016/j.cmet.2010.12.001.
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